<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03740243</url>
  </required_header>
  <id_info>
    <org_study_id>1175806</org_study_id>
    <nct_id>NCT03740243</nct_id>
  </id_info>
  <brief_title>Buprenorphine vs Buprenorphine/Naloxone on the Effects of Maternal Symptomatology</brief_title>
  <official_title>Comparison of Buprenorphine vs Buprenorphine/Naloxone on the Effects of Maternal Symptomatology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stony Brook University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stony Brook University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assesses the efficacy of buprenorphine/naloxone vs buprenorphine on maternal
      withdrawal symptoms and drug cravings.

      This is a randomized controlled trial to a cohort of pregnant women seeking
      medication-assisted treatment for opioid use disorders. Half of participants will receive
      buprenorphine, while the other half of participants receive a combination of
      buprenorphine/naloxone
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Buprenorphine and Buprenorphine/naloxone each are used to treat opioid use disorders in
      pregnancy.

      Buprenorphine has many preferential characteristics over methadone including decreased risk
      of maternal overdose, lower incidence of preterm labor, less frequent clinical visits,
      shorter duration of neonatal hospital stay and treatment for neonatal abstinence syndrome.
      Recent studies have found that increasing the dosing frequencies of buprenorphine is more
      efficacious to prevent maternal withdrawal symptoms, improve compliance, and theoretically
      produce better pregnancy outcomes.

      Buprenorphine/naloxone, a combination opioid of buprenorphine and naloxone, has also been
      investigated as an alternative to treatment and maintenance for opioid use disorder. The
      advantage of the combination of buprenorphine with naloxone is that it reduces the potential
      for abuse. As a partial mu opioid agonist, buprenorphine alone has the capacity to induce
      typical opioid effects such as euphoria, which are enhanced when the drug is taken
      intravenously. By combining buprenorphine with naloxone, an opioid antagonist, the capacity
      for buprenorphine to be abused is reduced.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No enrollment
  </why_stopped>
  <start_date type="Actual">November 30, 2018</start_date>
  <completion_date type="Actual">March 22, 2020</completion_date>
  <primary_completion_date type="Actual">March 22, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compliance antepartum</measure>
    <time_frame>From entry into the study until delivery (through study completion, an average of 9 months which is duration of the pregnancy)</time_frame>
    <description>To compare compliance with buprenorphine versus buprenorphine/naloxone medication-assisted treatment (MAT) in pregnant women. Compliance will include the incidence of urine toxicology testing positive for illicit substances during prenatal care and at the time of admission for delivery.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compliance postpartum</measure>
    <time_frame>2 month period postpartum</time_frame>
    <description>To compare compliance with buprenorphine versus buprenorphine/naloxone medication-assisted treatment (MAT) in the postpartum period. Compliance will include the incidence of urine toxicology testing positive for illicit substances from the time of discharge from the hospital following the delivery over a 2 month period postpartum (postpartum period).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dosing antepartum</measure>
    <time_frame>From entry into the study until delivery (through study completion, an average of 9 months which is duration of the pregnancy)</time_frame>
    <description>Evaluate all women for the need a significant dosing change in buprenorphine or buprenorphine/naloxone (&gt;50% increase or decrease) during pregnancy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dosing postpartum</measure>
    <time_frame>2 month period postpartum</time_frame>
    <description>Evaluate all women for the need a significant dosing change in buprenorphine or buprenorphine/naloxone (&gt;50% increase or decrease) from the hospital following the delivery over a 2 month period postpartum (postpartum period).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maternal Outcomes Withdraw Scoring</measure>
    <time_frame>Duration of pregnancy and 2 months of postpartum period</time_frame>
    <description>Prenatal Clinical Opioid Withdraw Scale (COWS) score and drug cravings score (0 to 48 score)
Score interpretation:
5-12 = Mild 13-24 = Moderate 25-36 = Moderately Severe More than 36 = Severe Withdrawal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal Outcome Metabolites</measure>
    <time_frame>At delivery of newborn</time_frame>
    <description>Umbilical cord blood levels of metabolites of buprenorphine (norbuprenorphine, buprenorphine glucuronide, and norbuprenorphine glucuronide) which are obtained from the umbilical cord after delivery of the baby (one time specimen for evaluation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Placental dysmaturity</measure>
    <time_frame>At delivery of newborn</time_frame>
    <description>Placental histology (obtained at delivery - pathology specimen)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal Outcomes</measure>
    <time_frame>Birth until discharge from hospital (performed during hospitalization of newborn from 0 to 30 days of life)</time_frame>
    <description>Neonatal Abstinence Syndrome (NAS) rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal stay</measure>
    <time_frame>Birth to newborn discharge home (from day 0 through 120 days of life)</time_frame>
    <description>Duration of newborn inpatient hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Newborn</measure>
    <time_frame>At birth</time_frame>
    <description>Gestational age at birth (range 23 to 43 weeks)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Opioid-use Disorder</condition>
  <arm_group>
    <arm_group_label>buprenorphine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Buprenorphine 2 mg to 8 mg daily: Light to moderate history of opioid use (heroin, oxycodone, etc.) and/or Clinical Opioid Withdraw Scale (COWS) scores 5-24
Buprenorphine 8 mg to 16 mg daily: Heavy history of opioid use (heroin, oxycodone, etc.) and/or Clinical Opioid Withdraw Scale (COWS) scores 25-36+</description>
  </arm_group>
  <arm_group>
    <arm_group_label>buprenorphine/naloxone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Buprenorphine/naloxone 4 mg/1 mg daily once daily or twice daily (BID): Light to moderate history of opioid use (heroin, oxycodone, etc.) and/or Clinical Opioid Withdraw Scale (COWS) scores 5-24
Buprenorphine/naloxone 8 mg/2 mg daily once daily or twice daily (BID): Heavy history of opioid use (heroin, oxycodone, etc.) and/or Clinical Opioid Withdraw Scale (COWS) scores 25-36+</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine/naloxone</intervention_name>
    <description>Buprenorphine/naloxone tablet or film</description>
    <arm_group_label>buprenorphine/naloxone</arm_group_label>
    <other_name>suboxone, bunavail, zubsolv</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine</intervention_name>
    <description>Buprenorphine tablet</description>
    <arm_group_label>buprenorphine</arm_group_label>
    <other_name>subutex, belbuca, butrans,sublocade</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age and older

          -  With a confirmed viable intrauterine pregnancy

          -  Opioid Use Disorder

          -  Care in a Stony Brook Medicine OBGYN clinical office sites

          -  Medication-assisted treatment through Stony Brook Medicine OBGYN office sites

        Exclusion Criteria:

          -  Known or suspected allergy to buprenorphine or buprenorphine/naloxone

          -  Carrying a fetus with known aneuploidy or anomaly
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>As this study pertains only to pregnant patients seeking treatment for opioid use disorders, females are the only biologically plausiable participants.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David J Garry, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stony Brook University</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Committee on Obstetric Practice. Committee Opinion No. 711: Opioid Use and Opioid Use Disorder in Pregnancy. Obstet Gynecol. 2017 Aug;130(2):e81-e94. doi: 10.1097/AOG.0000000000002235.</citation>
    <PMID>28742676</PMID>
  </results_reference>
  <results_reference>
    <citation>Bastian JR, Chen H, Zhang H, Rothenberger S, Tarter R, English D, Venkataramanan R, Caritis SN. Dose-adjusted plasma concentrations of sublingual buprenorphine are lower during than after pregnancy. Am J Obstet Gynecol. 2017 Jan;216(1):64.e1-64.e7. doi: 10.1016/j.ajog.2016.09.095. Epub 2016 Sep 26.</citation>
    <PMID>27687214</PMID>
  </results_reference>
  <results_reference>
    <citation>Caritis SN, Bastian JR, Zhang H, Kalluri H, English D, England M, Bobby S, Venkataramanan R. An evidence-based recommendation to increase the dosing frequency of buprenorphine during pregnancy. Am J Obstet Gynecol. 2017 Oct;217(4):459.e1-459.e6. doi: 10.1016/j.ajog.2017.06.029. Epub 2017 Jun 29.</citation>
    <PMID>28669739</PMID>
  </results_reference>
  <results_reference>
    <citation>Chavan NR, Ashford KB, Wiggins AT, Lofwall MR, Critchfield AS. Buprenorphine for Medication-Assisted Treatment of Opioid Use Disorder in Pregnancy: Relationship to Neonatal Opioid Withdrawal Syndrome. AJP Rep. 2017 Oct;7(4):e215-e222. doi: 10.1055/s-0037-1608783. Epub 2017 Dec 7.</citation>
    <PMID>29226017</PMID>
  </results_reference>
  <results_reference>
    <citation>Debelak K, Morrone WR, O'Grady KE, Jones HE. Buprenorphine + naloxone in the treatment of opioid dependence during pregnancy-initial patient care and outcome data. Am J Addict. 2013 May-Jun;22(3):252-4. doi: 10.1111/j.1521-0391.2012.12005.x.</citation>
    <PMID>23617867</PMID>
  </results_reference>
  <results_reference>
    <citation>Geber WF, Schramm LC. Congenital malformations of the central nervous system produced by narcotic analgesics in the hamster. Am J Obstet Gynecol. 1975 Dec 1;123(7):705-13.</citation>
    <PMID>907</PMID>
  </results_reference>
  <results_reference>
    <citation>Fudala PJ, Bridge TP, Herbert S, Williford WO, Chiang CN, Jones K, Collins J, Raisch D, Casadonte P, Goldsmith RJ, Ling W, Malkerneker U, McNicholas L, Renner J, Stine S, Tusel D; Buprenorphine/Naloxone Collaborative Study Group. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003 Sep 4;349(10):949-58.</citation>
    <PMID>12954743</PMID>
  </results_reference>
  <results_reference>
    <citation>Jumah NA, Edwards C, Balfour-Boehm J, Loewen K, Dooley J, Gerber Finn L, Kelly L. Observational study of the safety of buprenorphine+naloxone in pregnancy in a rural and remote population. BMJ Open. 2016 Oct 31;6(10):e011774. doi: 10.1136/bmjopen-2016-011774.</citation>
    <PMID>27799240</PMID>
  </results_reference>
  <results_reference>
    <citation>Lund IO, Fischer G, Welle-Strand GK, O'Grady KE, Debelak K, Morrone WR, Jones HE. A Comparison of Buprenorphine + Naloxone to Buprenorphine and Methadone in the Treatment of Opioid Dependence during Pregnancy: Maternal and Neonatal Outcomes. Subst Abuse. 2013;7:61-74. doi: 10.4137/SART.S10955. Epub 2013 Mar 14.</citation>
    <PMID>23531704</PMID>
  </results_reference>
  <results_reference>
    <citation>Mendelson J, Jones RT. Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: why the 4:1 ratio for treatment? Drug Alcohol Depend. 2003 May 21;70(2 Suppl):S29-37. Review.</citation>
    <PMID>12738348</PMID>
  </results_reference>
  <results_reference>
    <citation>Nguyen L, Lander LR, O'Grady KE, Marshalek PJ, Schmidt A, Kelly AK, Jones HE. Treating women with opioid use disorder during pregnancy in Appalachia: Initial neonatal outcomes following buprenorphine + naloxone exposure. Am J Addict. 2018 Mar;27(2):92-96. doi: 10.1111/ajad.12687. Epub 2018 Feb 23.</citation>
    <PMID>29473258</PMID>
  </results_reference>
  <results_reference>
    <citation>Poon S, Pupco A, Koren G, Bozzo P. Safety of the newer class of opioid antagonists in pregnancy. Can Fam Physician. 2014 Jul;60(7):631-2, e348-9. English, French.</citation>
    <PMID>25022635</PMID>
  </results_reference>
  <results_reference>
    <citation>Simojoki K, Vorma H, Alho H. A retrospective evaluation of patients switched from buprenorphine (Subutex) to the buprenorphine/naloxone combination (Suboxone). Subst Abuse Treat Prev Policy. 2008 Jun 17;3:16. doi: 10.1186/1747-597X-3-16.</citation>
    <PMID>18559110</PMID>
  </results_reference>
  <results_reference>
    <citation>Strain EC, Harrison JA, Bigelow GE. Induction of opioid-dependent individuals onto buprenorphine and buprenorphine/naloxone soluble-films. Clin Pharmacol Ther. 2011 Mar;89(3):443-9. doi: 10.1038/clpt.2010.352. Epub 2011 Jan 26.</citation>
    <PMID>21270789</PMID>
  </results_reference>
  <results_reference>
    <citation>Wiegand SL, Stringer EM, Stuebe AM, Jones H, Seashore C, Thorp J. Buprenorphine and naloxone compared with methadone treatment in pregnancy. Obstet Gynecol. 2015 Feb;125(2):363-8. doi: 10.1097/AOG.0000000000000640.</citation>
    <PMID>25569005</PMID>
  </results_reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 15, 2018</study_first_submitted>
  <study_first_submitted_qc>November 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2018</study_first_posted>
  <last_update_submitted>March 22, 2020</last_update_submitted>
  <last_update_submitted_qc>March 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stony Brook University</investigator_affiliation>
    <investigator_full_name>David Garry DO</investigator_full_name>
    <investigator_title>Director, Maternal Fetal Medicine</investigator_title>
  </responsible_party>
  <keyword>opioid use disorder</keyword>
  <keyword>Buprenorphine/naloxone</keyword>
  <keyword>Buprenorphine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
    <mesh_term>Buprenorphine, Naloxone Drug Combination</mesh_term>
    <mesh_term>Naloxone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>In regards to the participants and neonates' health information, care will be taken to ensure privacy. All data and specimens will be coded with a case number and de-identified, and exported to a REDcap application system (secure data file approved by Institutional Review Board). The REDcap application data will be kept on the department's secure, shared institutional, server space.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan: Protocol and SAP</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 27, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/43/NCT03740243/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 27, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/43/NCT03740243/ICF_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol: COWS questionnaire and Brief Substance Cravings scale</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 28, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/43/NCT03740243/Prot_002.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

